Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05680194

Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients

Conditions: Breast Cancer Female

Sex: Female
Ages: 65 Years – 100 Years
Enrollment: 1000
Sponsor: Peking Union Medical College Hospital

Location: China

Summary

The elderly patients over 65 years old with breast cancer have concomitant diseases, poor tolerance to conventional treatment, and the specific prognosis of breast cancer is relatively good. Previous studies on breast cancer have almost excluded elderly breast cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis and treatment needs of elderly breast cancer patients. The establishment of a prognosis model for elderly breast cancer patients can provide personalized treatment programs. This is important for prolonging the survival time of patients and improving the quality of life. This project plans to observe the relationship between prognosis and pathological staging, molecular typing, and concomitant diseases of elderly breast cancer patients in combination with immune genes, and establish a prognosis model of elderly breast cancer and verify it. This project is expected to establish a new prognostic model for elderly breast cancer patients, accurately judge the prognosis of patients, and provide a new basis for hierarchical and personalized treatment of elderly breast cancer.

Eligibility Criteria

Inclusion Criteria:female patients with breast cancer≥65 Years Oldpatients with breast cancer received operation in Peking Union Medical College Hospitaltreatment regimen was made in Peking Union Medical College HospitalExclusion Criteria:patients with metastasispatietns with recurrencepatients without pathological information

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05680194). StuddyBuddy aggregates publicly available trial information.